REGULAXIS developes molecules which it has proprietary international patents or global licenses. This strong industrial property gives to the company significant advantages for the development of its business and for its economic and financial base.

The R&D of the company is focused on main human therapeutic domains

Tissue regeneration
Tissue regeneration such as Osteoarthritis also known as degenerative arthritis or degenerative joint disease, a group of symptoms involving degradation of joints, including articular cartilage and subchondral bone.
Growth dysfunctions
Neurodegenerative diseases
Metabolic syndrome

Regulaxis is engaged in the R&D of molecules that can advantageously be proposed to treat

  • Reconstitution and repair of articular cartilage by stimulation of chondrocytes, cartilage-forming cells, necessary for the treatment of osteoarthritis and cartilage recovery after traumatic lesions.
  • Acromegaly which is a syndrome that results when, in adult, an excess of GH is produced by the anterior pituitary.
  • Cancers, namely Neuroendocrine tumors (NETs), and multiple endocrine neoplasia (MEN) as well as Prostate cancer.

Our Collaborations